Assessing potential of psilocybin for depressive disorders-Reference-Cited by-同舟云学术

Assessing potential of psilocybin for depressive disorders

Published:2023-10-03 Issue:10 Volume:32 Page:887-900
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Kozak Zofia¹,Johnson Matthew W.²,Aaronson Scott T.¹³

Affiliation:

1. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA

2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA

3. The Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt, Baltimore, MD, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2023.2273493

Reference78 articles.

1. Depression Is the Leading Cause of Disability Around the World

2. World Health Organization. Depression and other common mental disorders: global health estimates [Internet]. World Health Organization; 2017 [cited 2023 Jul 14]. Report No.: WHO/MSD/MER/2017.2. Available from: https://apps.who.int/iris/handle/10665/254610.

3. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States

4. Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews

5. The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies;Journal of Neural Transmission;2024-03-30

2. New evidence for flexible psilocybin dosing in patients with treatment-resistant depression;Med;2024-03

3. Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?;European Archives of Psychiatry and Clinical Neuroscience;2024-02-27

4. Editorial: New trends in the treatment of mood disorders;Frontiers in Psychology;2024-01-09

5. Innovations in group‐based psilocybin‐assisted therapy of major depression in patients with cancer;Cancer;2023-12-18